Analytical Data
-
基因名
EPHA5
- Application
-
别名
EHK-1; EK7; BSK; EHK1; HEK7; TYRO4; EphA5; Rek7; TYRO4HEK7CEK7
-
种属
Cynomolgus
-
表达系统
HEK293
-
标签
C-His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
XP_005555256.1
-
表达区间
S56-P573
-
蛋白长度
Partial
-
分子量
76 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
EPHA5, a member of the Eph receptor tyrosine kinase family, plays a crucial role in various biological processes, including cell adhesion, migration, and tissue development. Its involvement in neural development and synaptic plasticity has garnered significant interest in understanding neurodegenerative diseases and cancers. Abnormal expression of EPHA5 has been associated with various pathological conditions, including Alzheimer's disease and certain types of tumors, indicating its potential as a therapeutic target. The study of EPHA5 recombinant proteins allows researchers to investigate its structural and functional properties, providing insights into its signaling mechanisms and interactions with ephrin ligands. Additionally, reconstituting EPHA5 in vitro can facilitate the development of therapeutic strategies, such as monoclonal antibodies or small molecules aimed at modulating its activity. As the field of targeted therapies continues to evolve, exploring EPHA5's pathway could lead to breakthroughs in personalized medicine, paving the way for novel strategies in treating diseases linked to its dysfunction. Understanding EPHA5 through recombinant protein studies thus represents a pivotal step in elucidating its roles in health and disease.
